<DOC>
	<DOC>NCT00509236</DOC>
	<brief_summary>The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.</brief_summary>
	<brief_title>Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Participant has T2DM. Participant is on dialysis on day of signing informed consent. Participant is unlikely to conceive or uses acceptable methods of birth control: hormonal contraceptive, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, or vasectomy. Participant has hemoglobin A1c ≥7% and ≤9% measured at or within 2 weeks prior to Visit 4/Week 2. Participant is ≥85% compliant with study medication during the singleblind placebo runin (as determined by tablet/capsule count) and compliant with diet, exercise and other runin treatments during the runin period. Participant has a history of type 1 diabetes mellitus or a history of ketoacidosis. Participant is losing weight in a weight loss program and is not in the maintenance phase (defined as &lt;2 kg weight loss in 2 months), or intends to be involved in weight loss intervention outside that prescribed by the study. Participant has a clinically significant hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia). Participant has cirrhosis or active liver disease. Participant has been on dialysis for &lt; 6 months. Participant has been diagnosed with a significant cardiovascular disorder and has new or worsening signs or symptoms of congestive heart failure within 3 months of signing informed consent. Participant has severe active peripheral vascular disease. Participant has a history of malignancy ≤ 5 years prior to signing informed consent, or &gt; 5 years without documentation of remission/cure. Participant is under treatment for hyperthyroidism. Participant has a hypersensitivity or contraindication to glipizide.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>